Clinical trial No longer in our active list Phase 3 Interventional Ages 18 and up

Evaluating Dato-DXd and Durvalumab for Treating Certain Types of Breast Cancer

Official title: A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)

Run by AstraZeneca · NCT06112379 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study is testing a new combination treatment for certain types of breast cancer to see if it works better than the standard therapy.

More Breast Cancer trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment1728 (estimated)
SponsorAstraZeneca
Industry-sponsored
Drugs / interventionsdurvalumab, pembrolizumab, chemotherapy
Locations355 sites (Daphne, Alabama and 354 other locations)
Trial IDNCT06112379 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older with histologically confirmed Stage II or III TNBC or hormone receptor-low/HER2-negative breast cancer.

Probably not a fit

Patients with a history of prior invasive breast malignancy or those with distant disease may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase III clinical trial is a multicenter, global study that compares the effectiveness and safety of neoadjuvant Dato-DXd combined with durvalumab against neoadjuvant pembrolizumab plus chemotherapy in patients with untreated triple-negative breast cancer (TNBC) or hormone receptor-low/HER2-negative breast cancer. Participants will receive either treatment followed by adjuvant therapy to assess the primary outcomes of pathologic complete response (pCR) and event-free survival (EFS). The study aims to determine if the new combination therapy offers superior results compared to the standard treatment.

Why it matters

Potential benefit: If successful, this study could provide a more effective treatment option for patients with aggressive forms of breast cancer.

How similar studies have gone: Other studies have shown promising results with similar immunotherapy approaches in breast cancer, indicating potential for success in this trial.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participant must be ≥ 18 years, at the time of signing the ICF.
* Histologically confirmed Stage II or III unilateral or bilateral primary invasive TNBC or hormone receptor-low/HER2-negative breast cancer
* ECOG PS of 0 or 1
* Provision of acceptable tumor sample
* Adequate bone marrow reserve and organ function
* Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies and aligned with protocol requirements.

Exclusion criteria:

* History of any prior invasive breast malignancy
* History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 5 years before randomization.
* active or prior documented autoimmune or inflammatory disorders.
* Evidence of distant disease.
* Clinically significant corneal disease.
* Has active or uncontrolled hepatitis B or C virus infection.
* Known HIV infection that is not well controlled.
* Uncontrolled infection requiring i.v. antibiotics, antivirals or antifungals; suspected infections; or inability to rule out infections.
* Known to have active tuberculosis infection
* Mean resting corrected QTcF interval \> 470 ms obtained from ECG
* Uncontrolled or significant cardiac disease.
* History of non-infectious ILD/pneumonitis
* Has severe pulmonary function compromise
* Any prior or concurrent surgery, radiotherapy or systemic anticancer therapy for TNBC or hormone receptor-low/HER2-negative breast cancer
* For females only: is pregnant (confirmed with positive serum pregnancy test) or breastfeeding, or planning to become pregnant.
* Female participants should refrain from breastfeeding from enrolment throughout the study and for at least 7 months after last dose of study intervention, or as dictated by local PI for SoC if longer.
* Concurrent use of systemic hormone replacement therapy or oral hormonal contraception

Where it's running

  • Research Site
    Daphne, Alabama, United States
    Recruiting
  • Research Site
    Goodyear, Arizona, United States
    Recruiting
  • Research Site
    Tucson, Arizona, United States
    Recruiting
  • Research Site
    Jonesboro, Arkansas, United States
    Recruiting
  • Research Site
    Rogers, Arkansas, United States
    Recruiting
  • Research Site
    Bakersfield, California, United States
    Recruiting
Show 44 more locations
  • Research Site
    Fullerton, California, United States
    Recruiting
  • Research Site
    Los Angeles, California, United States
    Recruiting
  • Research Site
    Orange, California, United States
    Recruiting
  • Research Site
    Santa Barbara, California, United States
    Recruiting
  • Research Site
    Santa Rosa, California, United States
    Recruiting
  • Research Site
    Torrance, California, United States
    Recruiting
  • Research Site
    Van Nuys, California, United States
    Recruiting
  • Research Site
    Aurora, Colorado, United States
    Recruiting
  • Research Site
    Fort Collins, Colorado, United States
    Recruiting
  • Research Site
    Longmont, Colorado, United States
    Recruiting
  • Research Site
    Bridgeport, Connecticut, United States
    Recruiting
  • Research Site
    New Haven, Connecticut, United States
    Recruiting
  • Research Site
    Fort Myers, Florida, United States
    Recruiting
  • Research Site
    Jacksonville, Florida, United States
    Recruiting
  • Research Site
    Saint Petersburg, Florida, United States
    Recruiting
  • Research Site
    West Palm Beach, Florida, United States
    Recruiting
  • Research Site
    Atlanta, Georgia, United States
    Recruiting
  • Research Site
    Atlanta, Georgia, United States
    Recruiting
  • Research Site
    Chicago Ridge, Illinois, United States
    Recruiting
  • Research Site
    Des Moines, Iowa, United States
    Recruiting
  • Research Site
    Edgewood, Kentucky, United States
    Recruiting
  • Research Site
    Louisville, Kentucky, United States
    Recruiting
  • Research Site
    Baton Rouge, Louisiana, United States
    Recruiting
  • Research Site
    Annapolis, Maryland, United States
    Recruiting
  • Research Site
    Boston, Massachusetts, United States
    Recruiting
  • Research Site
    Detroit, Michigan, United States
    Recruiting
  • Research Site
    Grand Rapids, Michigan, United States
    Recruiting
  • Research Site
    Traverse City, Michigan, United States
    Recruiting
  • Research Site
    Burnsville, Minnesota, United States
    Recruiting
  • Research Site
    Minneapolis, Minnesota, United States
    Recruiting
  • Research Site
    Columbia, Missouri, United States
    Recruiting
  • Research Site
    Omaha, Nebraska, United States
    Recruiting
  • Research Site
    Henderson, Nevada, United States
    Recruiting
  • Research Site
    Camden, New Jersey, United States
    Recruiting
  • Research Site
    East Brunswick, New Jersey, United States
    Recruiting
  • Research Site
    New Brunswick, New Jersey, United States
    Recruiting
  • Research Site
    Santa Fe, New Mexico, United States
    Recruiting
  • Research Site
    New York, New York, United States
    Recruiting
  • Research Site
    Charlotte, North Carolina, United States
    Recruiting
  • Research Site
    Durham, North Carolina, United States
    Recruiting
  • Research Site
    Blue Ash, Ohio, United States
    Recruiting
  • Research Site
    Canton, Ohio, United States
    Recruiting
  • Research Site
    Eugene, Oregon, United States
    Recruiting
  • Research Site
    Portland, Oregon, United States
    Recruiting

+305 more sites. See ClinicalTrials.gov for the full list.

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.